Research programme: antibody encoded oncolytic viruses - BioInvent/Transgene
Latest Information Update: 28 Jan 2022
At a glance
- Originator BioInvent International; Transgene
- Class Antibodies; Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants; Cytotoxic T-lymphocyte antigen 4 inhibitors; Immunologic cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for preclinical development in Solid-tumours in France (Parenteral)
- 28 Jan 2022 No recent reports of development identified for preclinical development in Solid-tumours in Sweden (Parenteral)
- 09 Jun 2021 Transgene has patent protection for oncolytic virus (OV) backbone VVcopTK-RR- in Japan